Active clinical trials for "Macular Degeneration"

This non-interventional, retrospective, observational, noncomparative, non-randomized, single-arm, multi-centre study included patients (≥50 years) diagnosed with neovascular age-related macular degeneration (nAMD) in at least 1 eye. Anonymized data of patients treated with brolucizumab intravitreal injection (IVI) who had received the first dose of brolucizumab between 01 October 2020 and 31 March 2021 was collected. Patients could either be treatment-naïve or previously treated with single or a combination of other IVI of anti-vascular endothelial growth factors (VEGFs). The primary outcome measure was the change in fluid levels (intra-retinal fluid [IRF], sub-retinal fluid [SRF], and pigment epithelial detachment [PED]) from baseline to Month 3. Secondary outcome measures included change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), number of brolucizumab injections, and safety (number of adverse events [AEs]). Descriptive statistics were tabulated for the demographic and clinical characteristics as well as outcome variables.

Neovascular age-related macular degeneration (nAMD) is characterized by the abnormal growth of blood vessels from the choroid into the subretinal space which leads to sub- and intraretinal fluid accumulation, hemorrhages and subretinal fibrosis with progressive loss of central vision. Intravitreal anti-VEGF treatment is the standard of care. Intravitreal anti-VEGF application might temporarily increase intraocular pressure due to a volume effect. It remains unclear if repeated injections might have an impact on retinal capillary perfusion. Therefore this study aims to investigate the vascular microcirculation differences between patients who received longterm intravitreal Anti-VEGF treatment and patients who recently started Anti-VEGF treatment using Optical Coherence tomography Angiography (OCTA).

Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma. Without timely diagnosis and adequate medical intervention, the visual impairment can become a great burden on individuals as well as the society. It is estimated that China has 110 million patients under the attack of diabetes, 180 million patients with hypertension, 120 million patients suffering from high myopia and 200 million people over 60 years old, which suggest a huge population at the risk of blindness. Despite of this crisis in public health, our society has no more than 3,000 ophthalmologists majoring in fundus oculi disease currently. As most of them assembling in metropolitan cities, health system in this field is frail in primary hospitals. Owing to this unreasonable distribution of medical resources, providing medical service to hundreds of millions of potential patients threatened with blindness is almost impossible. To solve this problem, this software (MCS) was developed as a computer-aided diagnosis to help junior ophthalmologists to detect 13 major retina diseases from color fundus photographs. This study has been designed to validate the safety and efficiency of this device.

In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.

Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50. Neovascular AMD, the most serious and severe form, is characterized by the appearance, spread and growth of subretinal new vessels. One of the major molecular mediators is vascular endothelial growth factor (VEGF). Intra-vitreous (IVI) injection of an anti-VEGF can slow the progression of neovascular AMD and stabilize vision in the majority of cases. Aflibercept (Eylea®) is one of the anti-VEGF molecules approved in Belgium to treat neovascular AMD. At the start of its use, aflibercept was first injected monthly and then according to the PRN "reactive" protocol (Pro Renata). Over time, a new treatment strategy has emerged: the "treat-and-extend" (T&E). This is individualized patient care, the objective of which is to reduce the frequency of injections while ensuring inactivity of the disease. This begins with the loading dose, i.e. 3 injections given 4 weeks apart. Thereafter, the interval is lengthened in increments of 1 or 2 weeks provided that the visual and anatomical results remain stable. In the event of deterioration, the interval is shortened while keeping a minimum of 4 weeks between each IVI. The efficacy and safety of aflibercept, when used in a proactive T&E regimen, was demonstrated in the randomized controlled trial, ALTAIR. However, data on T&E used in practice is still lacking. routine, and particularly the number of injections and treatment intervals over a minimum 24 month treatment period. The aim of this retrospective study carried out at the CHU Brugmann is to determine the number of injections and the intervals necessary to have encouraging results in terms of visual acuity, over a treatment period of at least one year.

This study will explore experience of AMD caregivers in order to develop a core outcome set (COS) for age related macular degeneration (AMD) randomised controlled trials (RCTs) trying to capture what research outcomes are important from their perspective. People 18 years of age and older who have been AMD caregivers for at least 6 months may be eligible for this study. The aim is to conduct three focus groups lasting approximately one hour. The plan is to enrol 18-24 participants (6-8 participants per each of 3 focus groups).Two researchers will be involved in conducting the focus groups. A moderator will ensure fluid discussion, while the second investigator will be taking notes and audio-recording the discussion.

Aflibercept is the most recently developed VEGF inhibitor with a recombinant fusion protein consisting of human VEGF receptor extracellular domains from receptors 1 and 2 (VEGFR1 and VEGFR2) fused to the Fc domain of human IgG. Although both ranibizumab and bevacizumab have been shown not to have harmful effects on corneal endothelium, the effect of intravitreal aflibercept on human corneal endothelium has not been reported so far. Considering the functional importance of the corneal endothelium, particularly in aged population, the present study was designed to evaluate the in vivo toxicity of aflibercept on human corneal endothelial cells in patients with neovascular AMD. This study showed that intravitreal injection of clinically effective doses of aflibercept for four times on average during the 6-month period do not induce any harmful effect on human corneal endothelium evaluated by specular microscopy. Further prospective, large-scale, prolonged studies are needed to confirm that intravitreal aflibercept can be used safely without any corneal toxicity to treat neovascular AMD.

Including eye health, nutrition plays a vital role for the sustainability of individuals health life. There is an increasing global concern about the issues related with eye health. In 2010, in order to take attention to these issues, World Health Organization (WHO) defined the main reasons of vision disorders as refraction defects of eye diseases (43 %), cataract (33 %), glaucoma (2 %), age-related macular degeneration (AMD) (1 %), diabetic retinopathy (1 %) and undetermined natural reasons (18 %). This report also stated the three biggest reasons of blindness as cataract (51 %), glaucoma (8 %) and AMD (5 %). AMD is a multi-factorial disease in which the genetic predisposition plays important role with environmental factors and metabolic conditions, except for age. Especially cigarette is the secondary important risk factor for dry-type AMD. In the Age Related Eye Disease Study (AREDS), it was stated that AMD prevalence is higher in white races, compared with races which are not white. At the same time, AREDS searched the effect of diet supplements on the progression of AMD disease. In terms of the patients followed for six years, it was reported that the formulation C and E vitamins, beta carotene and zinc decreased the progression risk of AMD from middle levels to advanced levels by 34 %. In AREDS-2 study completed in 2012, it was shown that the extraction of beta carotene from the formulation and the decrease of zinc did not affect the progression rate of the disease. In the group using beta carotene, including persons who were used to smoke but gave up at least one year ago, the rate of becoming lung cancer was observed as substantially high. Moreover, the use of lutein and zeaxanthin instead of beta carotene in the formula did not increase the risk of lung cancer. In addition, it was shown that omega-3 fatty acids did not decrease risk progression. In current data, the effect of the intake of carotenoid and antioxidant increased with diet on AMD is not coherent. Likewise, the epidemiological evidences about the relation between diet fat intake and AMD are contradictory. The consumption of fatty fish is related with increased poly-unsaturated fatty acid intake and decreases the risk of AMD. However, it was reported the high rate of total fat intake in other studies as risk factor for AMD. In another study, there was not any important relation found between diet fat intake and AMD occurrence after the correction of other variables. In the interventional AREDS-2 study, it was reported that the additional intake of long-chain omega-3 poly-unsaturated fatty acids did not have any beneficial effect. The pathophysiological mechanism responsible from the possible relation between obesity and AMD is not clearly known. There are various hypotheses about how obesity causes AMD. In the first hypothesis, obesity can cause AMD after obesity increases systematic oxidative stress. In the second hypothesis, obesity can play a role in AMD pathophysiology as the cause of hyperleptinemia. The studies also prescribed that inflammation could play a role in the progression of AMD and also showed that plasma fibrinogen and other inflammation indicators could be related with late AMD. In Pathologies Oculaires Liées à l'Age (POLA) study made with the participation of many Europeans, it was observed that the progression of late AMD increased by two times in obese individuals and in early AMD, obesity did not affect the progression of disease. In the treatment of this disease which have age-related progression, proper nutrition, vitamin/mineral/supplement usage and the development of precautionary strategies play an important role. When compared with Body Mass Index (BMI), it was found that the measure of abdominal obesity (waist/hip rate and waist circumference) was the better determinant of chronic diseases such as diabetics and cardiovascular disease. Some evidences in the United States of America indicated that the relation between waist/hip rate and AMD gave stronger results when compared with the relation between BMI and AMD. For middle age cohort, after six years of follow-up, a group of researchers reported that the decrease of waist/hip rate also decreased the risk of AMD and the results were the same for waist circumference, even if the evidences were weak. In another study, it was reported that the increase of waist/hip rate or waist circumference also increased the progression of AMD. This study was planned with the aim of determining the occurrence of AMD by evaluating dietary total antioxidant capacity, diet components and some anthropometric measures of individuals having age related macular degeneration (AMD). In the study, the possible effect of nutrition on the occurrence of disease was evaluated by comparing healthy individuals with dietary total antioxidant capacity and some anthropometric measures of individuals with AMD.

Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Currently, there is no safe way to obtain cells from the eye to study. But researchers now can turn other types of cells, like skin or blood, into induced pluripotent stem (iPS) cells. These can be grown in a lab and turned into other types of cells, like cells from the eye. This will allow researchers to understand and treat diseases of the eye such as AMD. Objectives: To establish a bank of samples that can be changed into other cell types, such as eye cells, to better understand diseases such as AMD. Also to test drugs in order to treat various eye diseases. Eligibility: People who provided DNA samples in another protocol (07-EI-0025) Design: Participants will be screened with their data from the previous protocol. Participants with select genetic variants will be chosen and contacted via phone. Participants will have a punch skin biopsy. The skin will be washed. A numbing medication will be injected. A small piece of skin will be removed with a biopsy tool. The site will be covered with a dressing. They will receive instructions on how to care for the area. They will have follow-up visits if needed for clinical care for the area. Participants may be asked to return if their first sample did not provide enough cells for the lab. Participants sample will be developed into eye cells. The cells will be used to understand diseases and test new drugs.

There is a need to investigate the effectiveness of IVT aflibercept injection in routine clinical practice. The aim of this study is to collect 12-month real-world clinical data from treatment-naïve nAMD patients who started first-line treatment with IVT aflibercept injection, according to the SmPC (Summary of Product Characteristics) and the SERV (Spanish Society of Retina and Vitreous) guidelines. The effectiveness of IVT aflibercept will be assessed by the changes in VA (Visual Acuity) and CRT (Central Retinal Thickness) during treatment.